The Preferred Biotech Resource in Asia-Pacific
Vol 19, No 07, July 2015
Biotech in China
Kh-biotech cover


Eye on China


Conferences ListingConferences

Pharma Sales
Biocon receives marketing authorization for novel biologic itolizumab for psoriasis
Biocon, Asia's premier biotechnology company received marketing authorization from the Drugs Controller General of India (DCGI) for its novel biologic itolizumab, anti-CD6 molecule, for the treatment of chronic plaque psoriasis.

Itolizumab, is a first in class therapy with a unique Mechanism of Action (MOA) and an excellent safety profile as indicated during the 52 week Phase III multi-centric clinical study conducted in India. It is the second novel biologic developed by Biocon at Asia's largest biotech hub in Bangalore.

This approval paves the way for the launch of Biocon's Alzumab TM in India, later during 2013. Alzumab TM is a differentiated biologic drug with a superior safety profile compared to other approved biologic therapies given its very low opportunistic infection rates. A novel biologic indicated for the treatment of Moderate-to-Severe Psoriasis, Alzumab TM will be marketed by Biocon's Immunotherapy Division. Alzumab TM, will be manufactured and formulated as an infusion drug at Biocon's biopharma manufacturing facility at Biocon Park, Bangalore.

Commenting on this development Ms. Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon said, "We are very excited to receive this marketing authorization for Itolizumab from DCGI which will enable Biocon to introduce this novel, first in class biologic for the treatment of psoriasis patients in India. This is our second novel biologic that we have developed in India, BioMab EGFR, an anti-cancer monoclonal antibody, being the first. This approval paves the way for us to extend clinical development for other indications like rheumatoid arthritis, multiple sclerosis and vitiligo. We also intend to file a US IND shortly to enable us to embark on a global clinical development plan. This is a defining moment for Biocon as it reaches a significant milestone in its mission of delivering affordable innovation to patients worldwide."

Alzumab (TM) is expected to provide a safe and effective treatment option for psoriasis, a socially debilitating disease affecting 2-3 % of Indian population. The global psoriasis market size is estimated to cross $8 billion by 2016.

Itolizumab has shown promising preclinical and clinical efficacy in other auto immune diseases like rheumatoid arthritis and multiple sclerosis. The company aims to file a US IND in 2013 to facilitate global clinical trials in psoriasis, rheumatoid arthritis and other indications as a subcutaneous formulation. Biocon plans to develop this molecule with a global partner for various markets across the world.

Click here for the complete issue.